title: Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.
abstract: BACKGROUND
  Pre-existing antibodies to influenza virus neuraminidase may provide protection against infection influenza viruses containing novel hemagglutinin (HA). The aim of our study was to evaluate serum neuraminidase-inhibiting (NI) antibodies against А/California/07/2009(H1N1) [H1N1/2009pdm] and А/New Caledonia/20/1999(H1N1) [H1N1/1999] influenza viruses in relation with the age of participants and hemagglutination-inhibition (HI) antibody levels. Anti-H1N1/2009pdm neuraminidase and anti-H1N1/1999 neuraminidase antibody levels were measured in total 219 serum samples from Russian healthy peoples of various ages examined before and a year after pandemic strain appearance. We adjusted peroxidase-linked lectin micro-procedure to measure NI antibody titers using the reassortant A/H7N1 influenza viruses based on A/equine/Prague/1/56(H7N7). Also, HI antibody titers were estimated against H1N1/2009pdm, H1N1/1999 and a panel of seasonal A/H1N1 influenza viruses.
  
  
  RESULTS
  In sera samples collected during the fall of 2010, mean titers of specific HI and NI antibodies to H1N1/2009pdm were 2-2.1 times lower than antibody levels against H1N1/1999. Of the 163 individuals examined, 58 (35.6%) had NI anti-H1N1/2009pdm antibody titers > 1:20, compared to 93 (57.1%) who had NI anti-H1N1/1999 antibody titers > 1:20. There were low correlations between HI and NI antibody levels against either H1N1/1999 or H1N1/2009pdm in the same serum samples. The 24 adults born between 1957 and 1977 expressed very low levels of NI antibodies to A/H1N1 influenza viruses. Persons with low HI anti-H1N1/2009pdm titers but positive to seasonal A/H1N1 demonstrated significantly higher NI anti-A/H1N1 antibody titers than unexposed subjects. In 2005 cross-reactive NI anti-H1N1/2009pdm antibody titers > 1:20 were detected among 7.1% of young people.
  
  
  CONCLUSIONS
  Our study confirmed that contact with seasonal influenza viruses may have contributed to generating the cross-reacting anti-H1N1/2009pdm NI antibodies which were detected in the sera of 18-20 years old people examined before the pandemic virus active circulation. The lowest levels of antibodies to the neuraminidase of N1 subtype were in the group of participants born during the circulation of influenza A/H2N2 or A/H3N2 viruses. The low correlation between HI and NI antibody titers suggests that NI antibody detection can be used as an additional test to evaluate the immune response after influenza infections or immunizations.
authors.affiliation: Institute of Experimental Medicine, Russian Academy of the Medical Sciences, Acad. Pavlov's Street, 12, Saint Petersburg, 197376, Russian Federation. desheva@mail.ru.
authors.forename: Yulia A
authors.initials: YA
authors.lastname: Desheva
authors.affiliation: Institute of Experimental Medicine, Russian Academy of the Medical Sciences, Acad. Pavlov's Street, 12, Saint Petersburg, 197376, Russian Federation. smolonogina@mail.ru.
authors.forename: Tatiana A
authors.initials: TA
authors.lastname: Smolonogina
authors.affiliation: Institute of Experimental Medicine, Russian Academy of the Medical Sciences, Acad. Pavlov's Street, 12, Saint Petersburg, 197376, Russian Federation. sveta.donina@gmail.com.
authors.forename: Svetlana A
authors.initials: SA
authors.lastname: Donina
authors.affiliation: Institute of Experimental Medicine, Russian Academy of the Medical Sciences, Acad. Pavlov's Street, 12, Saint Petersburg, 197376, Russian Federation. vaccine@mail.ru.
authors.forename: Larisa G
authors.initials: LG
authors.lastname: Rudenko
mesh_terms: D000293:Adolescent; D000328:Adult; D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D056738:Cross Protection; D003429:Cross Reactions; D005260:Female; D064368:Healthy Volunteers; D006385:Hemagglutination Inhibition Tests; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D006801:Humans; D056724:Immunity, Humoral; D053118:Influenza A Virus, H1N1 Subtype / Q000235:genetics / Q000276:immunology; D053121:Influenza A Virus, H2N2 Subtype / Q000235:genetics / Q000276:immunology; D053122:Influenza A Virus, H3N2 Subtype / Q000235:genetics / Q000276:immunology; D057916:Influenza A Virus, H7N1 Subtype / Q000235:genetics / Q000276:immunology; D053126:Influenza A Virus, H7N7 Subtype / Q000235:genetics / Q000276:immunology; D007251:Influenza, Human / Q000097:blood* / Q000276:immunology / Q000821:virology; D008297:Male; D008875:Middle Aged; D009439:Neuraminidase / Q000276:immunology*; D016865:Reassortant Viruses / Q000235:genetics / Q000276:immunology; D012426:Russia; D014764:Viral Proteins / Q000276:immunology; D055815:Young Adult
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D014764:Viral Proteins; D009439:Neuraminidase